Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
319
resultados
Última actualización
10/09/2026 [10:22:00]
Resumen de: EP4803610A1
The present invention relates to a biohybrid robot comprising an eye/brain organoid, a motor neuron spheroid and a muscle bundle, and a method for fabricating the same, and a versatile biohybrid robot according to the present invention may cause movement of muscle cells by an electrophysiological signal generated from the eye/brain organoid like a human motor system using light stimulation and a neurotransmitter. It is expected to be utilized in disease models that stimulate human signal transduction systems by combining various neurodegenerative disease models, such as Parkinson's and Alzheimer's disease models, with eye tumor models in the future, and be utilized in the fabrication of drug screening platforms using the operation of versatile biohybrid robots composed of biological tissues.
Resumen de: EP4804206A1
The present invention relates to a next generation sequencing (NGS) method for disease prediction through analysis of nail-derived germline mutations and somatic mutations, and a system therefor. Specifically, the present invention relates to a nail-based NGS analysis method for predicting or diagnosing a disease, comprising the steps of: isolating gDNA from nails; and analyzing the isolated gDNA using NGS.
Resumen de: WO2025093893A1
The present invention relates to methods of measuring the presence and/or levels of a combination of five biomarkers in a sample, said biomarkers being neurofilament light (NfL) polypeptide, glial fibrillary acidic protein (GFAP), β-Amyloid 1-42 (Aβ1-42), β-Amyloid 1-40 (Aβ1-40), and phosphorylated Tau (p-Tau181, pTau-231 and/or p-Tau217). The methods can be used to predict the subject's risk or likelihood of having and/or developing Alzheimer's disease, thus also provided is a method of predicting a subject's risk or likelihood of having and/or developing Alzheimer's disease, said method comprising measuring the presence of and/or the levels of the combination of five biomarkers. Further provided is a method of prognosing or diagnosing Alzheimer's disease in a subject comprising the methods of measuring the presence of and/or the levels of the combination of five biomarkers, and a method of treating Alzheimer's disease comprising predicting a subject's risk or likelihood of developing or having Alzheimer's disease using the methods of measuring the presence and/or levels of the combination of five biomarkers and administering a treatment if the risk or likelihood exceeds a threshold value.
Resumen de: US2022034912A1
The present invention refers to p53 sequence and post translational modifications (PTMs) and to their use as biomarkers in the diagnosis of neurodegenerative disease and cognitive decline and/or in the prognosis of Alzheimer's disease at different stages and/or of neurodegenerative disease in a biological sample. The invention also provides for a 1) diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of neurodegenerative disease, including Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), fronto-temporal dementia (FTD), Lewi's Body (LB), and vascular dementia (VD) in a subject, by evaluating the PTMs to the said p53 linear sequence protein and possible cut of its full sequence specifically in human plasma of patients; and 2) prognosis of AD in CU and MCI patients.
Resumen de: US20260258354A1
The present invention relates to a method for generating a microglia-sufficient brain organoid comprising the step of incubating primitive-like macrophage cells with a brain organoid that is between about 15 to about 30 days old in cerebral organoid medium comprising CSF-1 in a low attachment cell culture vessel to generate microglia cells. The present invention also relates to a microglia-sufficient brain organoid obtained by the method as described herein.
Resumen de: US20260256717A1
In alternative embodiments, provided are drugs and companion diagnostics, or therapeutic drug combinations and a companion diagnostic comprising a dried blood spot or a volumetric dried blood spot, or an at-home high-volume liquid blood, collection device, including products of manufacture and kits, and methods, for using them. In alternative embodiments, provided are novel methods for dosaging therapeutic drug compositions. In alternative embodiments, provided are artificial intelligence (AI)-enabled therapeutic drug compositions (bMEDs™), including bMEDs™ amifampridine for Lambert Eaton Myasthenic Syndrome (LEMS), bMEDs™ deflazacort to Duchenne Muscular Dystrophy (DMD), bMEDs™ propranolol for Infantile Hemangioma, bMEDs™ serabelisib for PIK3CA-Related Overgrowth Spectrum (PROS), bMEDs™ sirolimus for Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon (“KHE w/KMP”), bMED™ everolimus for TSC-associated epilepsy, TSC-associated SEGA, TSC-associated renal angiomyolipoma, breast cancer, pNET, renal cancer, or allograph organ rejection prophylaxis, and bMEDs™ for rare diseases as provided herein.
Resumen de: WO2025179149A1
Provided herein are methods and systems for diagnosing pathological conditions using machine learning and artificial intelligence models. An exemplary method can include loading an abundance matrix that represents mass spectrometry reads of a sample of a plurality of volatile organic compounds (VOCs) extracted from a biological sample. The abundance matrix can represent each of the plurality of VOCs in a mass-to-charge ratio dimension, an abundance dimension, and a retention time dimension. The method can include providing the abundance matrix to a machine-learning model. The machine- learning model can be trained on abundance matrixes of biomarkers of VOCs collected from healthy and diseased subjects. The method can include receiving, from the machine-learning model, a prediction of a state of a disease state.
Resumen de: WO2026183319A1
Described herein are methods of identifying cell-type specific proteins that are transmembrane on or internal to extracellular vesicles (EVs).
Resumen de: US20260259227A1
0000 Provided herein are methods for determining whether a disorder is susceptible to treatment with a plasma kallikrein inhibitor and methods for identifying a subject as a candidate for treatment with a plasma kallikrein inhibitor. Provided herein are methods of identifying a subject as having or being at risk for a disorder and methods of treating a disorder in a subject. Also provided herein are methods of evaluating effectiveness of a treatment in a subject.
Resumen de: US20260258105A1
0000 The disclosure relates to the engineering of IL-35 cytokine polypeptides to achieve improved therapies for inflammatory diseases and conditions. Accordingly, aspects of the disclosure relate to a polypeptide comprising SEQ ID NO:2, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:2, wherein the one or more amino acid substitutions comprise K23, R74, R195, R197, or combinations thereof. Further aspects relate to a polypeptide comprising SEQ ID NO:4, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:4, wherein the one or more amino acid substitutions comprise C74. Further aspects relate to a polypeptide comprising SEQ ID NO:6, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:6, wherein the one or more amino acid substitutions comprise C34.
Resumen de: US20260259201A1
Provided herein are compositions, systems, and methods comprising effector proteins, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the editing, detecting and/or engineering of nucleic acids.
Resumen de: WO2025179269A1
The disclosure provides a therapeutic composition comprising pooled, culture-expanded human umbilical cord-derived mesenchymal stromal cells (hucMSCs) derived from at least four and up to twelve donors, which can be reproduced with batch to batch consistency. These cells exhibit consistent marker expression profiles, enhanced and consistent secretion of therapeutic factors, and potent immunomodulatory activities after at least ten to thirty population doublings. The composition, formulated with a pharmaceutically acceptable carrier, is designed for clinical applications addressing inflammatory, immune, and degenerative conditions.
Resumen de: US20260259203A1
0000 Disclosed is a method that combines high throughput and flexible nature of a cell-free protein microarray with the quantitative capability of surface plasmon resonance to detect>400 different protein interactions in <1 hour. A method of detecting interactions between a targeting agent and one or more proteins of interest is disclosed. The method includes producing a set of proteins of interest using a cell-free protein expression system; providing the set of proteins of interest on a protein microarray wherein each spot in the array comprises a protein of interest; contacting the protein microarray with a targeting agent that binds to one or more of the set of proteins of interest; and detecting the binding of the targeting agent to the set of proteins of interest using surface plasmon resonance imaging (SPRi), thereby detecting the targeting agent and one or more proteins of interest in the micro array.
Resumen de: US20260259229A1
A common molecular signature of elevated oxidative stress is detected in blood samples from individuals with fatigue syndromes, including LC, ME-CFS, and lupus patients reporting fatigue. Analysis can be performed with one or more of flow cytometry, bulk RNA-seq analysis, mass spectrometry, and systems chemistry analysis. Elevated reactive oxygen species (ROS) were found, as well as differences in glutathione ROS clearance pathways and markers of oxidative damage.
Resumen de: US20260258495A1
The present invention relates to a biomarker for the early diagnosis of Alzheimer's disease and a use thereof, and more particularly, the present invention relates to: a biomarker composition for the early diagnosis of Alzheimer's disease, the biomarker composition comprising one or more genes selected from the group consisting of alpha-2-macroglobulin (A2M), creatine kinase M-type (CKM), filamin-A (FLNA), integral alpha-IIb (ITGA2B), alpha-1-acid glycoprotein 2 (ORM2), phospholipid transfer protein (PLTP), haptoglobin (HP), sulfhydryl oxidase 1 (QSOX1), protein-glutamine gamma-glutamyltransferase 2 (TGM2), filamin C (FLNC), heat shock protein 70 (HSP70) and lysomal alpha-mannosidase (MAN2B1), or a protein expressed from the genes; a method for the early diagnosis of Alzheimer's disease; a diagnostic kit for the early diagnosis of Alzheimer's disease; and a method for providing information for predicting and diagnosing Alzheimer's disease.
Resumen de: WO2026183555A1
Methods of treating a neurodegenerative disease in a subject in need thereof are provided. Exemplary methods include providing a biological sample from the subject; measuring an NfL530 peptide concentration in the biological sample; measuring at least one of an NfL284 peptide concentration and an NfL101 peptide concentration in the biological sample; determining at least one of an NfL530/NfL284 ratio and an NfL530/NfL101 ratio; and treating the subject based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio. In some embodiments, the biological sample is selected from whole blood, plasma, and cerebrospinal fluid. In some embodiments, the subject is determined to have ALS based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio.
Resumen de: US20260259202A1
0000 Proper functioning of the human body relies on the organization of cells in 3D space. A cell's function and fate are determined by its biomolecule composition and 3D environment. The spatial identification of proteins, RNAs, DNAs, and other biomolecules in a tissue thus provides a powerful map to decipher how cells build tissues and become diseased. Thus, described herein are methods and compositions for assessing biomolecule identity (the present invention features methods and compositions for assessing biomolecule identity (e.g., genes (DNA, RNA), DNA and RNA modifications, proteins, protein modifications, lipids, sugars, metals), and abundance (e.g., RNA expression levels, protein translation levels) in a 3D tissue sample.
Resumen de: US20260259219A1
Provided is a method for measuring proteomic cysteine redox status in a sample obtained from a bodily fluid of a subject, the method comprising: (i) providing said sample, wherein the sample comprises a plurality of different proteins that comprise cysteine residues, a proportion of which are in reduced form and a proportion of which are in reversibly oxidised form; (ii) contacting the sample with a first label that selectively labels the reduced cysteine thiols of the plurality of different proteins; (iii) contacting the sample with a reducing agent that reduces the reversibly oxidised cysteine residues to form reduced cysteine thiols; (iv) contacting the sample with a second label that labels the reduced cysteine thiols formed in step (iii), wherein the second label is distinguishable from the first label by mass spectrometry, (v) processing the sample for analysis by mass spectrometry; and (vi) analysing the sample by mass spectrometry to measure at least the relative abundance of identified peptides labelled with the first label and corresponding identified peptides labelled with the second label, thereby providing a measure of the proteomic cysteine redox status of the sample. The invention also provides related methods for biomarker discovery and for predicting presence of a liver disease and/or cancer, such as hepatocellular carcinoma (HCC) in a subject.
Resumen de: AU2026216833A1
24521425_1 (GHMatters) P44915AU02 Provided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins. ug u g
Resumen de: US20260258118A1
0000 The present invention relates to a method for detecting markers of fibroblast activation in a patient by sandwich immunoassay to identify patients, particularly cancer patients who would benefit from anti-TGFβI therapy. The markers of fibroblast activation may be selected from the N-terminal pro-peptide of Collagen III (Pro-C3), the N-terminal pro-peptide of Collagen VI (Pro-C6), the N-terminal pro-peptide of Collagen I (Pro-C1) and/or an internal sequence in the N-terminal region of type 3 collagen (P3NP). The invention also provides an anti-TGFβI therapy for use in the treatment of cancer and/or fibrosis.
Resumen de: US20260256858A1
0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.
Resumen de: WO2026183240A1
The presently described and claimed technology relates to high-throughput automated methods for detecting brain derived tau (BD-tau) in a biological sample using an immunoassay analyzer.
Resumen de: US20260259204A1
Described herein are biosensor microarrays comprising detector polypeptide monolayers substantially free of contaminants. Also provided are methods for generation of such biosensor microarrays by capture of polypeptides by arrays comprising capture moieties and associated sensors.
Resumen de: WO2026181008A1
The invention provides methods of assessing abundance of GABAergic somatostatin positive interneurons (SST+ cells) in living brain tissue of a subject by calculating a polygenic risk score using genomic variants of genes co-expressed with SST mRNA and their cis expression quantitative trait loci (cis-eQTLs); or where the genomic variants associated with SST+ cell abundance are variants directly associated with inter-individual variability in SST cell type proportions estimated from bulk RNA-seq data. Also provided are related diagnostic methods.
Nº publicación: WO2026183546A1 03/09/2026
Solicitante:
MERCK SHARP & DOHME LLC [US]
MERCK SHARP & DOHME LLC
Resumen de: WO2026183546A1
A three-dimensional (3D) bioprinted model of a forebrain cortex is designed to quantify neurite outgrowth across a hydrogel bridge. The 3D bioprinted model includes two cell-laden compartments formed using a first hydrogel matrix, separated by a hydrogel bridge formed from a second, stiffer hydrogel matrix. The model may fit within standard 96-well plate formats, enabling medium-throughput screening applications. The model was validated using Alzheimer's disease forebrain cortical populations, demonstrating significant reductions in neurite outgrowth from Alzheimer's disease populations compared to controls.
BOPI
Sede Electrónica
